PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
618 episodes - English - Latest episode: 6 days ago - ★★★★★ - 7 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Johanna C. Bendell, MD - Stories From the Pancreatic Cancer CaseBook: Taking the Road to Improved Outcomes With Modern Therapeutic Concepts and Innovative Treatments
August 05, 2019 23:00 - 1 hour VideoGo online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the valid...
John Allan, MD - Taking a New Look at Mantle Cell Lymphoma in the Era of Novel Agent Classes: From Innovative Concepts to Practical Applications of Evidence
July 31, 2019 23:00 - 21 minutes VideoGo online to PeerView.com/TVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology reviews recent evidence for novel therapeutics for the management of mantle cell lymphoma and offers practical insight on integrating clinical evidence into patient care and management, including for patients who have progressed after upfront therapy and who are candidates for second-line treatment. Upon completio...
Robert Dreicer, MD, MS, MACP, FASCO - New Concepts in Prostate Cancer Care: What Oncologists Need to Know to Optimize Patient Outcomes
July 29, 2019 23:00 - 1 hour VideoGo online to PeerView.com/NXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for prostate cancer has evolved rapidly in recent years, and research endeavors continue to expand treatment options, with significant implications for patients with early-stage and advanced disease. In addition to the approval of multiple second-generation anti-androgen therapies in nonmetastatic castration-resistant and metas...
David F. McDermott, MD - Redefining the Management of Advanced RCC: An Expert Tumor Board on Rational Selection, Sequencing, and Combination of Targeted Agents and Immunotherapy
July 26, 2019 23:00 - 1 hour VideoGo online to PeerView.com/FPP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, recorded from a live event at the 2019 American Society of Clinical Oncology Annual Meeting, a panel of kidney cancer experts offers case-centric discussion of key evidence that supports clinical decision-making through multiple lines of therapy in advanced RCC, as well as practical instruction on how to effectively and safely integrat...
Nathan H. Fowler, MD - A MasterClass on Innovative Therapy in B-Cell Lymphoma: Evidence, Clinical Guidance, and Insights on the Future of Patient Care
July 24, 2019 23:00 - 1 hour VideoGo online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other str...
Ezra Cohen, MD, FRCPSC, FASCO - Mapping Progress With Immune Checkpoint Inhibitors in Head and Neck Cancer: Expert Views on Immunotherapy as a Component of Multimodal Care
July 19, 2019 23:00 - 1 hour VideoGo online to PeerView.com/XFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Already a cornerstone of care for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), immune checkpoint inhibitors are being explored in earlier treatment settings and in combination with other pillars of SCCHN care (such as surgery and radiotherapy). In this MasterClass activity, based on a recent live symposium hel...
Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era
July 17, 2019 23:00 - 1 hour VideoGo online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have eme...
The Emergence of Oral Therapy as a Pillar of Care in B-Cell Lymphoma: Insights and Expert Opinions From the Hematology-Oncology Team
July 15, 2019 23:00 - 1 hour VideoGo online to PeerView.com/AWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology and oncology experts discuss the emergence of novel, orally administered therapeutics as management options for patients with B-cell lymphoma. This activity also features the perspectives of a patient with small lymphocytic lymphoma and his experience of oral therapy during the course of his therapeutic journey. Upon complet...
Robert D. McBane, II, MD - Taking a New Look at Cancer-Associated Venous Thromboembolism: How Is Emerging Evidence Influencing Guidelines & Practice?
July 12, 2019 23:00 - 30 minutes VideoGo online to PeerView.com/TGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in venous thromboembolism (VTE) reviews the latest clinical science and guidelines pertaining to cancer-associated VTE prophylaxis and treatment. This video-based program also focuses on strategies to help learners prepare for the practical integration of direct oral anticoagulants (DOACs) in cancer-associated VTE and illustr...
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies
July 10, 2019 23:00 - 33 minutes VideoGo online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completio...
Jessica Donington, MD - The Expanding Role of Immunotherapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Thoracic Surgeons
July 03, 2019 23:00 - 1 hour VideoGo online to PeerView.com/CPZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New evidence from clinical trials assessing immunotherapies and combinations in lung cancer is emerging at a rapid pace. As a result, the treatment landscape is constantly evolving, and checkpoint inhibitor–based therapeutic approaches are establishing a foothold not only in advanced disease but in earlier stages of lung cancer as well. Immunotherapy ha...
Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life
July 01, 2019 23:00 - 17 minutes VideoGo online to PeerView.com/FCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in cardiology shares insight on recognizing and treating iron deficiency in patients with heart failure to achieve better outcomes and quality of life. Upon completion of this activity, participants should be better able to: Recognize the prevalence of iron deficiency (ID) in heart failure (HF) and its impac...
Neal D. Shore, MD, FACS - Advancing the Management of Urothelial Cancer With Immuno-Oncology and Targeted Approaches: Key Concepts for Urology Professionals on the Front Lines of Care
June 19, 2019 23:00 - 1 hour VideoGo online to PeerView.com/XNW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of advanced urothelial carcinoma of the bladder has undergone significant transformation in the last 2 years, with the emergence of immune checkpoint inhibitors as an essential component of the treatment armamentarium. Extensive research is also focused on newer approaches, such as antibody-drug conjugates and FGFR inhibitors, ...
Elizabeth A. Mittendorf, MD, PhD - On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
June 17, 2019 23:00 - 1 hour VideoGo online to PeerView.com/ZEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tremendous advances have been made in the treatment of many other subtypes of breast cancer, but treatment of triple-negative breast cancer (TNBC) has remained challenging. However, recent developments suggest that we are on the brink of a new era in TNBC therapy that now brings the novel class of cancer immunotherapies to this population of patients. I...
Stephen V. Liu, MD - A New Era Has Begun in the Treatment of SCLC: Navigating Novel Therapeutic Options and Strategies for Improving Patient Outcomes
June 14, 2019 23:00 - 1 hour VideoGo online to PeerView.com/UXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss various treatment options for small cell lung cancer (SCLC), including the rationale for using new therapies, key clinical trial data, and methods for integrating novel therapies into routine practice or through clinical trial participation. Upon completion of this activity, participants will be able to: Des...
Susan Blumel, RN, BSN - Navigating the CAR-T Cell Therapy Landscape in Hematologic Malignancies: Science and Practical Issues in Nursing Care
June 12, 2019 23:00 - 1 hour VideoGo online to PeerView.com/MFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor (CAR)-T cell therapy has recently emerged as an effective strategy for the management of multiple hematologic malignancies and offers hope for patients in leukemia, lymphoma, and myeloma settings. Oncology nurse professionals have a central role within the hematology-oncology team in guiding patients through their treatment con...
Gayle Jameson, MSN, ACNP-BC, AOCN - Clinical Advances in Pancreatic Cancer: The Oncology Nurse as a Leader and Advocate for Patients in a Changing Therapeutic Landscape
June 10, 2019 23:00 - 1 hour VideoOncology nurses are at the forefront of care for patients with pancreatic cancer, a much-feared disease whose management was for years characterized by modestly effective treatment options. The recent emergence of new cytotoxic platforms combined with rapid research on potent targeted therapies has made the role of the nurse as a caregiver and educator more important than ever, particularly because these new options differ greatly from conventional chemotherapy strategies. In this ac...
Barbara Barnes Rogers, CRNP, MN, AOCN, ANP-BC - An Oncology Nurse MasterClass on Oral Therapy in B-Cell Malignancies: Insights on Evidence, Practical Strategies, and the Nurse-Patient Partnership
June 07, 2019 23:00 - 1 hour VideoGo online to PeerView.com/TTY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent developments in B-cell lymphoma have increased the availability of novel, orally administered therapies. Nurse professionals managing patients with B-cell cancers play a central role in caring for patients who are eligible for treatment with oral therapeutics, including BTK, PI3K, and BCL-2 inhibitors, and immunomodulating agents. In this activit...
Kimberly Halla, MSN, FNP-C - Realizing the Promise of PARP Inhibitors in Solid Tumor Therapy: Guiding Oncology Nurses on the Advances and Challenges
June 05, 2019 23:00 - 1 hour VideoGo online to PeerView.com/KWE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView MasterClass, an expert panel of oncology nurse professionals presents the highlights of emerging science and clinical data on PARP inhibition in multiple solid tumors, assesses the role of companion diagnostic tests that identify patients with DDR mutations, as well as engage the audience in a stimulating discussion on the value of gene...
Kevin N. Sheth, MD - Exploring Unmet Needs in Large Hemispheric Infarction: Clinical Insights on Early Recognition and Emerging Therapy
June 02, 2019 23:00 - 29 minutes VideoGo online to PeerView.com/AKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses current and emerging interventions to reduce morbidity and mortality due to cerebral edema in patients with LHI. Upon completion of this activity, participants should be better able to: Apply evidence-based strategies for evaluation and management of large hemispheric infarction (LHI), Recognize the lat...
Leora Horn, MD, MSc, FRCPC - The Present and Future of Immunotherapy as a Key Component of the Treatment Arsenal for Locally Advanced & Earlier Stages of Lung Cancer
May 29, 2019 23:00 - 1 hour VideoGo online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What i...
Mollie Moran, APRN-CNP, AOCNP - Taking Aim at B-Cell Malignancies With BTK Inhibitors: Oncology Nurse Perspectives and Insights on Clinical Care
May 27, 2019 23:00 - 58 minutes VideoGo online to PeerView.com/XAC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium held during the Oncology Nursing Society’s (ONS) 44th Annual Congress, a panel of expert nurse faculty use a MasterClass/case-forum design to offer an in-depth review of BTK inhibitors, their therapeutic applications in B-cell malignancies, and the core nurse-focused practice issues that are central to ...
Richard S. Finn, MD / Laura M. Kulik, MD - Rethinking Care in Hepatocellular Carcinoma Amid Expanding Treatment Options: An Interdisciplinary Discussion
May 24, 2019 23:00 - 58 minutes VideoGo online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on stra...
John C. Byrd, MD - BTK Inhibition as an Anti-Cancer Strategy: Exploring a Model for Modern Targeted Therapy in Hematologic Malignancies and Beyond
May 22, 2019 23:00 - 1 hour VideoGo online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologi...
Robert Anders, MD, PhD - Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era
May 20, 2019 23:00 - 1 hour VideoGo online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and th...
Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges
May 17, 2019 23:00 - 59 minutes VideoIn this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing an...
Amy Goodrich, NP - Oncology Nurse Insights Into New Agent Classes and Research in B-Cell Lymphoma: Practical Issues and Evidence for the Front-Lines of Care
May 15, 2019 23:00 - 33 minutes VideoGo online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy ...
Justin F. Gainor, MD - New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations
May 09, 2019 23:00 - 1 hour VideoGo online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno...
Jason J. Luke, MD, FACP and Jennifer Wargo, MD, MMSc - Progress and Promise With Immunotherapy in Resectable Melanoma: Exploring New Evidence and Practical Issues With Checkpoint Inhibitors as Adjuvant Therapy
May 06, 2019 23:00 - 55 minutes VideoGo online to PeerView.com/EWW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Melanoma was the first clinical setting in which the use of immune checkpoint inhibitors was validated, leading to their rapid integration into the management of advanced disease. More recently, checkpoint inhibitors, based on phase 3 evidence, have claimed a role in the adjuvant setting. The future of adjuvant therapy for high-risk resectable melanoma ...
Benjamin Levy, MD - Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC: Evolving Science, New Standards of Care, and Implications for Multidisciplinary Management
May 03, 2019 23:00 - 1 hour VideoGo online to PeerView.com/CXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The best practices for management of patients with EGFR-mutant NSCLC continue to evolve as a result of advances in molecular testing and targeted treatment. Understanding what, when, and how to test, as well as how to select therapy, throughout the continuum of advanced NSCLC is paramount. In this activity, based on a recent live symposium held in San D...
Sagar Lonial, MD, FACP - Innovative Therapeutic Concepts for ASCT-Eligible Patients With Myeloma: Advancing Toward More Effective Care Across Treatment Settings
April 22, 2019 23:00 - 54 minutes VideoGo online to PeerView.com/QAJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in myeloma offer guidance on the selection and sequencing of innovative therapies for the ASCT-eligible patients with multiple myeloma, and addre...
Mitchell S. Cairo, MD - Attacking the Clinical Problem of VOD/SOS in HCT Recipients: Insights on Pathophysiology, Diagnosis, and Treatment
April 17, 2019 23:00 - 53 minutes VideoGo online to PeerView.com/SXH860 to view the entire program with slides. In this activity, based on a live symposium held during the 2019 Transplantation and Cellular Therapy (TCT) Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in hematology-oncology explore new developments related to the changing clinical consensus for managing veno-occlusive disease (VOD)/sinusoida...
Tanya Siddiqi, MD - Harnessing Recent Advances in CAR-T Cell Therapy for Leukemia and Lymphoma in the Era of Stem Cell Transplantation
April 15, 2019 23:00 - 52 minutes VideoGo online to PeerView.com/ZGE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy (TCT) Meetings in Houston, Texas, experts in hematology and oncology explore the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells and discuss exciting new developments with this innovative approach as well as its clinical potential and role in managing relapsed/refractory hem...
Leonard H. Calabrese, DO - Rheumatology, Immunology, and Immuno-Oncology Intersect: Navigating the Complexities of Immune Checkpoint Inhibition, Autoimmunity, and Immune-Related Adverse Events: How Can Rheumatologists Help Minimize the Risks and Maximize the Benefits of Cancer Immunotherapies?
April 12, 2019 23:00 - 1 hour VideoGo online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which...
Mark A. Socinski, MD - Expanding Options and Difficult Choices in the Initial Treatment of Advanced NSCLC: How to Personalize Treatment Decisions in the Era of Immuno-Oncology and Combinations
April 10, 2019 23:00 - 50 minutes VideoGo online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for...
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance
April 08, 2019 23:00 - 59 minutes VideoGo online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating th...
Madan H. Jagasia, MBBS, MS, MMHC - Innovative Therapies in Post-Transplant GVHD: Personal Insights From the Patient CaseBook
April 05, 2019 23:00 - 48 minutes VideoGo online to PeerView.com/XYM860 to view the entire program with slides. This activity utilizes a “CaseBook” format, offering learners a collection of patient case scenarios from the experts’ personal repertoire paired with analyses of how the treatment landscape in acute and chronic graft-versus-host disease (GVHD) is evolving. Hematology-oncology and bone marrow transplant professionals take a deep dive into the underlying immunology of GVHD and the latest evidence with innovative ...
Roy F. Chemaly, MD, MPH, FIDSA, FACP - Managing CMV in the New Era of Antiviral Therapy: Practical Considerations in the HCT Setting
April 03, 2019 23:00 - 49 minutes VideoGo online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive the...
Robert Dreicer, MD, MS, MACP, FASCO - Unraveling the Complexities of Prostate Cancer Management: Focus on Therapeutic Decisions for Early-Stage Disease and the Implications for Later-Stage Disease
March 29, 2019 23:00 - 1 hour VideoGo online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass an...
David F. McDermott, MD - Making Effective Therapeutic Choices for Advanced RCC in an Evolving Treatment Landscape: Personal Insights From the Patient CaseBook
March 27, 2019 23:00 - 1 hour VideoGo online to PeerView.com/FEJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Genitourinary Cancers Symposium in San Francisco, experts in renal cell carcinoma (RCC) dip into their patient “CaseBook” to offer insights from their own practice on how best to bridge the divide between clinical research and daily care in the management of RCC. Pairing analysis of the latest evidence with application of key clinical concepts t...
Luciano J. Costa, MD, PhD - Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact of Novel Platforms and Agent Classes Across the Spectrum of Care
March 20, 2019 23:00 - 33 minutes VideoGo online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical ...
Nathan H. Fowler, MD - Building Innovative Treatment Options for Patients With B-Cell Malignancies: Practical Insights on Clinical Evidence and Integration Strategies
March 15, 2019 23:00 - 53 minutes VideoGo online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews ...
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED
March 11, 2019 23:00 - 32 minutes VideoGo online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic...
Richard S. Finn, MD - Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes
March 08, 2019 23:00 - 1 hour VideoBreaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes
Anna F. Farago, MD, PhD - The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy
March 06, 2019 23:00 - 39 minutes VideoThe TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy
Guy Young, MD - Defining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A
March 01, 2019 23:00 - 38 minutes VideoDefining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A
Edward S. Kim, MD, FACP - Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?
February 27, 2019 23:00 - 28 minutes VideoBeyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?
Lynette M. Sholl, MD - Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do
February 25, 2019 23:00 - 1 hour VideoMolecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do
Arjun Balar, MD - Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes
February 19, 2019 23:00 - 58 minutes VideoKeeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes
Anas Younes, MD - Progress in Developing Novel Treatment Options for PTCL: Expert Views on Integrating Innovative Therapeutics Into Care
February 15, 2019 23:00 - 21 minutes VideoProgress in Developing Novel Treatment Options for PTCL: Expert Views on Integrating Innovative Therapeutics Into Care